Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of Inhibitor for advanced solid tumors treatment Ruchika Sharma4 April 2025 10:30 AM ISTSan Diego: Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an...
Bayer, Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor Ruchika Sharma27 March 2025 9:15 AM ISTBerlin: Bayer and Suzhou Puhe BioPharma Co., Ltd., a clinical-stage biotechnology company, have announced that they have entered into a global...
Dr Mike Graham to become new Head of RnD for Bayer Crop Science division Ruchika Sharma25 March 2025 11:15 AM ISTMonheim: Bayer has announced that Dr Mike Graham will become the new Head of Research & Development (R&D) for Bayer’s Crop Science...
Bayer Finerenone secures USFDA Priority Review designation for heart failure Ruchika Sharma17 March 2025 4:30 PM ISTBerlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug Administration (FDA) for finerenone...
Bayer arm advances Gene therapy clinical trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 Ruchika Sharma9 March 2025 10:30 AM ISTResearch Triangle Park: AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has announced...
Bayer begins Phase II trial with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumors Ruchika Sharma5 March 2025 9:00 AM ISTBerlin: Bayer has announced that the first patient has been enrolled in the global Phase II panSOHO study, an open-label clinical trial,...
Bayer-BlueRock Therapeutics bags USFDA Fast Track Designation for primary photoreceptor diseases treatment Ruchika Sharma3 March 2025 2:30 PM ISTBerlin: Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, has announced that...
Bayer files for approval of extended 6 month treatment interval for Eylea 8 mg in EU Ruchika Sharma11 Feb 2025 11:30 AM ISTBerlin: Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea...
Bayer seeks approval of finerenone in heart failure in EU Ruchika Sharma5 Feb 2025 11:30 AM ISTBerlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), seeking approval in...
Bayer seeks USFDA nod for Finerenone for adult patients with heart failure Ruchika Sharma11 Jan 2025 12:37 PM ISTBerlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration (US FDA) and to the...
Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer Ruchika Sharma8 Jan 2025 12:30 PM ISTOrion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National Medical Products...
Federal Court brings end to Roundup litigation in Australia: Bayer Ruchika Sharma6 Jan 2025 10:00 AM ISTLeverkusen: Bayer has announced that the Federal Court of Australia brought an end to the last Roundup case in Australia, closing all pending...
